The rise of generics

Article

The future of glaucoma medications and disease management

With patents expiring on current 'blockbuster' glaucoma medications, such as Xalatan (latanoprost), and the rise of generic alternatives an inevitability, OTEurope spoke with Professor Gábor Holló on his opinions and concerns for the future of glaucoma medications and its impact on disease management.

Q. Do you use generic glaucoma medications?

I currently only use one generic medication, timolol, which is not available to me in its original formulation.

Personally, I do not recommend generic topical glaucoma medications, especially not if there is a possibility of the patient accessing the original product. For topical glaucoma medication pharmacokinetic assessment of the generics is not possible (the eye cannot be sampled for such studies), thus comparison with the original product can be made only via evidence based clinical headtohead comparison studies. However, such studies are lacking. Also, it is important to remember that the various generics differ between each other, thus there is a poor level of standardization in Europe ('minor differences' of the ingredients are allowed but not defined, just like the bottle shape, transparency and droplet size). As a result of these variances the total amount of drug exposure is not sufficiently regulated and, therefore, may differ considerably between the various generics of the same original drug. In brief, the efficacy and the side effects may vary unlike with the original branded version. There was an interesting paper published in Clinical Therapeutics by Dr Sriram Sonty et al.1 and an interesting presentation by Dr Z. Mammo et al.2 at ARVO in 2010 revealing some of the issues created through the use of generics.

Q. Do you think that there are any myths surrounding generic glaucoma medications that should be dispelled?

Only that there are issues surrounding the variability of efficacy, which is something that is generally not considered and definitely should be as the interest of our patient and their health should be our top priority.

Q. Is there a critical need for generics manufacturers to use colour-coded packaging or possibly a need for strict guidelines about this?

There is a reason that colour-coded packaging has been employed in the branded versions of drugs, which is that a lot of patients suffering with glaucoma may not be able to see the labelling on a bottle and should they have multiple drops to take each day then these medications could be mixed up and some could be over-used. Additionally, it will help to use colour coding to prevent any switching between generic products, so I believe that it is important.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
© 2025 MJH Life Sciences

All rights reserved.